TaiMed Biologics - Asset Resilience Ratio

Latest as of September 2025: 19.25%

TaiMed Biologics (4147) has an Asset Resilience Ratio of 19.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does TaiMed Biologics carry for a breakdown of total debt and financial obligations.

Liquid Assets

NT$927.62 Million

≈ $29.22 Million USD Cash + Short-term Investments

Total Assets

NT$4.82 Billion

≈ $151.82 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2024)

This chart shows how TaiMed Biologics's Asset Resilience Ratio has changed over time. See 4147 total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down TaiMed Biologics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 4147 market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$927.62 Million	19.25%
Total Liquid Assets	NT$927.62 Million	19.25%

Asset Resilience Insights

Good Liquidity Position: TaiMed Biologics maintains a healthy 19.25% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

TaiMed Biologics Industry Peers by Asset Resilience Ratio

Compare TaiMed Biologics's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for TaiMed Biologics (2013–2024)

The table below shows the annual Asset Resilience Ratio data for TaiMed Biologics.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	21.50%	NT$1.07 Billion ≈ $33.86 Million	NT$5.00 Billion ≈ $157.50 Million	+11.27pp
2023-12-31	10.22%	NT$398.13 Million ≈ $12.54 Million	NT$3.89 Billion ≈ $122.68 Million	+1.17pp
2022-12-31	9.05%	NT$371.29 Million ≈ $11.70 Million	NT$4.10 Billion ≈ $129.21 Million	+0.18pp
2021-12-31	8.88%	NT$409.27 Million ≈ $12.89 Million	NT$4.61 Billion ≈ $145.26 Million	-3.28pp
2020-12-31	12.15%	NT$631.57 Million ≈ $19.90 Million	NT$5.20 Billion ≈ $163.71 Million	-7.33pp
2019-12-31	19.48%	NT$921.55 Million ≈ $29.03 Million	NT$4.73 Billion ≈ $149.04 Million	-10.28pp
2018-12-31	29.76%	NT$1.43 Billion ≈ $44.92 Million	NT$4.79 Billion ≈ $150.94 Million	-13.20pp
2017-12-31	42.97%	NT$1.93 Billion ≈ $60.95 Million	NT$4.50 Billion ≈ $141.87 Million	-7.68pp
2016-12-31	50.65%	NT$2.43 Billion ≈ $76.62 Million	NT$4.80 Billion ≈ $151.28 Million	-3.59pp
2015-12-31	54.24%	NT$2.67 Billion ≈ $84.19 Million	NT$4.93 Billion ≈ $155.21 Million	-5.04pp
2014-12-31	59.28%	NT$1.11 Billion ≈ $35.13 Million	NT$1.88 Billion ≈ $59.25 Million	+20.21pp
2013-12-31	39.07%	NT$279.25 Million ≈ $8.80 Million	NT$714.72 Million ≈ $22.52 Million	--

pp = percentage points

About TaiMed Biologics

TWO:4147 Taiwan Biotechnology

Market Cap

$425.63 Million

NT$13.51 Billion TWD

Market Cap Rank

#13376 Global

#502 in Taiwan

Share Price

NT$49.45

Change (1 day)

+0.10%

52-Week Range

NT$48.05 - NT$95.60

All Time High

NT$341.00